Kinoshita I, Vilquin J T, Guérette B, Asselin I, Roy R, Tremblay J P
Laboratoire de Neurobiologie, Université Laval, Hôpital de l'Enfant-Jésus, Québec, Canada.
Muscle Nerve. 1994 Dec;17(12):1407-15. doi: 10.1002/mus.880171210.
Transgenic CD1 mice expressing beta-galactosidase were used as myoblast donors. The myoblasts were injected in normal or mdx muscles previously irradiated and injected with notexin. Twenty-eight days after myoblast transplantation, the percentage of muscle fibers beta-glactosidase-positive was low in mice not immunosuppressed but was high (80%) in those treated with FK506. In mdx mice, muscle fibers expressing beta-galactosidase were also dystrophin positive. Most of the mice not treated with FK506 produced antibodies against the donor myoblasts. These results indicate that FK506 is a very useful immunosuppressive drug for myoblast transplantation in mice. Irradiation and notexin injection used in our experiments are, however, not feasible in humans. Other manipulations capable of increasing the participation of donor myoblasts to regeneration will therefore have to be identified before new clinical trials are attempted.
表达β-半乳糖苷酶的转基因CD1小鼠被用作成肌细胞供体。将成肌细胞注射到预先接受过辐射并注射了诺维毒素的正常或mdx小鼠肌肉中。成肌细胞移植28天后，未进行免疫抑制的小鼠中β-半乳糖苷酶阳性的肌纤维百分比很低，但在用FK506治疗的小鼠中该比例很高（80%）。在mdx小鼠中，表达β-半乳糖苷酶的肌纤维抗肌萎缩蛋白也呈阳性。大多数未用FK506治疗的小鼠产生了针对供体成肌细胞的抗体。这些结果表明，FK506是小鼠成肌细胞移植中一种非常有用的免疫抑制药物。然而，我们实验中使用的辐射和诺维毒素注射在人类中不可行。因此，在尝试新的临床试验之前，必须确定其他能够增加供体成肌细胞参与再生的操作。
